Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
Substudy C: The purpose of this substudy is to determine whether Lambda combined with
Ribavirin and Daclatasvir for 12 weeks is efficacious in treatment naïve subjects with
genotype 1b chronic HCV infection